REVIEW article
Front. Cell Dev. Biol.
Sec. Cell Death and Survival
Efferocytosis: A Therapeutic Strategy for Diabetes and its Vascular Complications
Provisionally accepted
- 1First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 2Zhengzhou University College of Medicine, Zhengzhou, China
- 3Tianjin First Central Hospital, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Thank you for your recognition of our manuscript very much. Thank you for giving us the opportunity to resubmit the revised manuscript "Efferocytosis: A Therapeutic Strategy for Diabetes and its Vascular Complications" as review. The manuscript ID is 1641748. We greatly appreciate your valuable suggestions, which have significantly improved the quality of the manuscript. We have made every effort to study and address our revision comments. Generally, we have provided a point-by-point response to the reviewer's comments and made appropriate modifications (in red) in the manuscript detailed responses to the comments are prepared and attached below. Efferocytosis primarily involves "find-me" signals, "eat-me" signals, and the process of phagocyte engulfment. Based on the suggestions from the editors and reviewers, we conducted an extensive literature review to provide a more detailed explanation of the molecular sequence in efferocytosis, aiming to enhance understanding of this process. Regarding efferocytosis and microvascular complications in diabetes, we have conducted a comprehensive literature search as per your recommendations and added relevant content, including information on specific mutations or dysregulated pathways, in hopes of increasing understanding of the underlying mechanisms. Furthermore, an increasing number of therapeutic approaches targeting efferocytosis have emerged, some of which have already entered clinical application, while others are still in the clinical trial phase. We have supplemented our discussion with literature on efferocytosis-based treatment strategies, aiming to demonstrate the potential for better clinical translation of these approaches. At the same time, we recognize that there are several neutral and negative findings that require clarification, in order to provide a more objective and balanced perspective for the public. In summary, the role of efferocytosis in microvascular complications of diabetes is traceable, but more basic research is needed. Our review will provide researchers with some new perspectives. Therefore, we strongly believe that the significance of this paper is remarkable. Once again, thank you for your invaluable input, and we have improved the manuscript according to your suggestions. We look forward to working with you and the reviewers to move this manuscript closer to publication in Frontiers in Cell and Developmental Biology.
Keywords: Efferocytosis, diabetes, diabetic vascular complications, Inflammation, immunology, efferocytosis-based therapy
Received: 06 Jun 2025; Accepted: 28 Oct 2025.
Copyright: © 2025 Song, Yuan, Li, Liu and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Gui Jun Qin, hyqingj@zzu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.